Allarity Therapeutics Q1 net loss per share narrows

Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc.

ALLR

0.00


Overview

  • Cancer drug developer's Q1 net loss per share narrowed from prior year

  • Company reduced outstanding share count through repurchase program

  • Cash and restricted cash rose to $29.8 mln at March 31, 2026


Outlook

  • Company expects stenoparib API manufacturing campaign to complete in Q3 2026 with no extra cash outlays

  • Allarity continues enrolling patients in Phase 2 ovarian and small cell lung cancer trials

  • Company expects new patent to extend stenoparib exclusivity by at least 11 years if issued


Result Drivers

  • COST CONTROL - Operating expenses declined slightly from prior year, reflecting financial discipline


Company press release: ID:nGNX9C3LHX


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$2.75 mln

Q1 Operating Expenses

$2.71 mln

Q1 Operating Income

-$2.69 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Allarity Therapeutics Inc is $9.75, about 545.7% above its May 14 closing price of $1.51


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.